Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011

LONDON, Sept. 21, 2023 . Leucid Bio ( " Leucid " or the " Company " ), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company ' s proprietary Lateral CAR platform,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials